Germany is a long-standing donor to Gavi and a leading official development assistance (ODA) donor and global health actor, with a partnership with Gavi dating back to 2006. Germany has committed more than €3.3 billion (US$ 3.6 billion) to Gavi through direct contributions and the Gavi COVAX AMC.
Germany hosted Gavi’s 2015 replenishment conference in Berlin, supporting and helping the Global Action Plan for Healthy Lives and Well-being for All with Ghana and Norway, and under its 2022 G7 Presidency initiated Gavi’s work on the African Vaccine Manufacturing Accelerator (AVMA).
Germany’s financial support increased significantly over successive strategic periods, with € 20 million (US$ 22 million) for Gavi 2.0 (2006–2010); €180 million (US$ 186 million) for Gavi 3.0 (2011–2015); €600 million (US$ 668 million) for Gavi 4.0 (2016–2020) and a further €600 million (US$ 716 million) for Gavi 5.0/5.1 (2021–2025). During the COVID-19 pandemic, Germany became one of Gavi’s largest COVAX donors, pledging €100 million in 2020, €980 million in 2021 and an additional €400 million in 2022 (US$ 1,589 million). Most recently, Germany pledged €600 million (US$ 682 million) for Gavi 6.0 (2026–2030). Germany remains Gavi’s largest AVMA donor, with US$ 318 million committed at the Paris launch of AVMA in June 2024, alongside US$ 50 million for Gavi’s First Response Fund. These commitments align strongly with Germany’s current interest in global health security, resilient vaccine supply, African manufacturing capacity and greater efficiency across the global health architecture.
*Local currency
†Proceeds are the funds that Gavi receives from donor commitments, either through direct donor payments, funding raised in advance against future donor pledges through IFFIm, or AMC funds released by the World Bank.
Hover over the bar chart above to view the data
Direct Contributions (including Matching Fund)
Non-US$ contributions are converted to US$ as follows:
IFFIm Contributions
Non-US$ contributions are converted to US$ as follows: